https://news.yahoo.co.jp/articles/899c563e085d3c9ff0f292eb6e70d42f4b5fa738

緊急事態条項の創設提言　財界人ら岸田首相に

https://news.yahoo.co.jp/articles/e4258e2f52711504482061a0cff0a2ef17607bf8

感染症の行動計画案を了承　医療逼迫時に緊急事態宣言

　政府は24日、専門家らによる新型インフルエンザ等対策推進会議を開催した。新型コロナウイルスの経験を踏まえ、重大な感染症への対応をまとめた「新型インフルエンザ等対策政府行動計画」の改定案を示し、大筋で了承された。医療逼迫時には総合的に判断し、必要に応じ緊急事態宣言を講じるとした。2013年に策定された政府行動計画は、約10年ぶりに抜本改定される。今年6月の閣議決定を目指す。 　新藤義孝感染症危機管理担当相は冒頭「感染症が社会に影響を与えることは想定していたが、想像を超える厳しい状況の中でこれまで積み上げてきたものに加えて、新たな対策を打たなければいけないことが分かってきた」と述べた。 　改定案では、幅広い感染症を想定。都道府県による外出自粛要請や就業制限、入院調整などの権限を明確化し、平時の備えに関する記載も充実させた。 　医療の逼迫時には総合的に判断、必要に応じまん延防止等重点措置や緊急事態宣言を講じるとした。状況の変化に応じて柔軟に対策を切り替え、国民生活や社会経済活動への影響軽減を図る。

https://news.yahoo.co.jp/articles/b7348de89191c25db7e1a72bf426dbc223f1fe65

感染症流行初期でも緊急事態宣言　行動計画、10年ぶり抜本改定

• 118

Bitchute動画
https://www.bitchute.com/video/zMXLUOyc80D3/

https://123210.net/wordpress/tatenaoshi/wp-content/uploads/sites/3/2024/04/ｱﾐﾄﾞﾝ_ﾄﾛｲﾀﾞﾙｺｱ.pdf

https://apps.who.int/gb/inb/pdf_files/inb7/A_INB7_3-en.pdf

SEVENTH MEETING OF THE INTERGOVERNMENTAL
NEGOTIATING BODY TO DRAFT AND NEGOTIATE
A WHO CONVENTION, AGREEMENT OR OTHER
INTERNATIONAL INSTRUMENT ON PANDEMIC
PREVENTION, PREPAREDNESS AND RESPONSE A/INB/7/3
Provisional agenda item 2 30 October 2023
Proposal for negotiating text
of the WHO Pandemic Agreement
A/INB/7/3
2
Contents
Chapter I. Introduction …………………………………………………………………………………………………………………… 5
Article 1. Use of terms …………………………………………………………………………………………………………… 5
Article 2. Objective and scope ………………………………………………………………………………………………… 6
Article 3. General principles and approaches…………………………………………………………………………….. 7
Chapter II. The world together equitably: Achieving equity in, for and through pandemic prevention,
preparedness and response ……………………………………………………………………………………….. 8
Article 4. Pandemic prevention and public health surveillance ……………………………………………………. 8
Article 5. One Health …………………………………………………………………………………………………………….. 9
Article 6. Preparedness, readiness and resilience ……………………………………………………………………… 10
Article 7. Health and care workforce ……………………………………………………………………………………… 11
Article 8. Preparedness monitoring and functional reviews……………………………………………………….. 12
Article 9. Research and development……………………………………………………………………………………… 12
Article 10. Sustainable production …………………………………………………………………………………………… 14
Article 11. Transfer of technology and know-how …………………………………………………………………….. 15
Article 12. Access and benefit-sharing …………………………………………………………………………………….. 16
Article 13. Global Supply Chain and Logistics………………………………………………………………………….. 18
Article 14. Regulatory strengthening ……………………………………………………………………………………….. 20
Article 15. Compensation and liability management ………………………………………………………………….. 20
Article 16. International collaboration and cooperation………………………………………………………………. 21
Article 17. Whole-of-government and whole-of-society approaches at the national level ……………….. 21
Article 18. Communication and public awareness ……………………………………………………………………… 22
Article 19. Implementation capacities and support …………………………………………………………………….. 22
Article 20. Financing …………………………………………………………………………………………………………….. 23
Chapter III. Institutional arrangements and final provisions ………………………………………………………………. 24
Article 21. Conference of the Parties ……………………………………………………………………………………….. 24
Article 22. Right to vote…………………………………………………………………………………………………………. 26
Article 23. Reports to the Conference of the Parties …………………………………………………………………… 26
Article 24. Secretariat ……………………………………………………………………………………………………………. 26
Article 25. Relationship with other international agreements and instruments ……………………………….. 27
Article 26. Reservations …………………………………………………………………………………………………………. 27
Article 27. Withdrawal…………………………………………………………………………………………………………… 27
Article 28. Amendments ………………………………………………………………………………………………………… 28
Article 29. Annexes ………………………………………………………………………………………………………………. 28
Article 30. Protocols ……………………………………………………………………………………………………………… 28
Article 31. Signature ……………………………………………………………………………………………………………… 29
Article 32. Ratification, acceptance, approval, formal confirmation or accession …………………………… 29
A/INB/7/3
3
Article 33. Entry into force …………………………………………………………………………………………………….. 30
Article 34. Settlement of disputes ……………………………………………………………………………………………. 30
Article 35. Depositary……………………………………………………………………………………………………………. 30
Article 36. Authentic texts ……………………………………………………………………………………………………… 30
A/INB/7/3
4
The Parties to the WHO Pandemic Agreement,
1. Recognizing that the World Health Organization is fundamental to strengthening pandemic
prevention, preparedness and response, as it is the directing and coordinating authority on international
health work,
2. Recalling the Constitution of the World Health Organization, which states that the enjoyment of
the highest attainable standard of health is one of the fundamental rights of every human being without
distinction of race, religion, political belief, economic or social condition,
3. Recognizing that the international spread of disease is a global threat with serious consequences
for lives, livelihoods, societies and economies that calls for the widest possible international cooperation
in an effective, coordinated, appropriate and comprehensive international response, while reaffirming
the principle of sovereignty of States Parties in addressing public health matters,
4. Noting with concern that the coronavirus disease (COVID-19) pandemic revealed serious
shortcomings in preparedness at national and global levels for the timely and effective prevention and
detection of, and response to, health emergencies,
5. Deeply concerned by the gross inequities at national and international levels that hindered timely
and equitable access to medical and other COVID-19 pandemic-related products, notably vaccines,
oxygen supplies, personal protective equipment, diagnostics and therapeutics,
6. Recognizing the critical role of whole-of-government and whole-of-society approaches at country
and community levels, and the importance of international, regional and cross-regional collaboration,
coordination and global solidarity in achieving sustainable improvements in pandemic prevention,
preparedness and response,
7. Recognizing the importance of ensuring political commitment, resourcing and attention across
sectors for pandemic prevention, preparedness and response,
8. Reaffirming the importance of multisectoral collaboration at national, regional and international
levels to: safeguard human health; detect and prevent health threats at the animal and human interface,
zoonotic spill-over and mutations; and sustainably balance and optimize the health of people, animals
and ecosystems in a One Health approach,
9. Reiterating the need to work towards building and strengthening resilient health systems, with
skilled and trained health and care workers, to advance universal health coverage and to adopt an
equitable approach to mitigate the risk that pandemics exacerbate existing inequities in access to health
services,
10. Recognizing that the protection of intellectual property rights is important for the development of
new medical products, and recalling that intellectual property rights do not, and should not, prevent
Member States from taking measures to protect public health, and further recognizing concerns about
the effects of intellectual property rights on prices,
11. Underscoring the importance of promoting the early, safe, transparent and rapid sharing of
samples and genetic sequence data of pathogens with pandemic potential, as well as the fair and
equitable sharing of benefits arising therefrom, taking into account relevant national and international
laws, regulations, obligations and frameworks, including the International Health Regulations, the
A/INB/7/3
5
Convention on Biological Diversity and the Nagoya Protocol on Access to Genetic Resources and the
Fair and Equitable Sharing of Benefits Arising from their Utilization, and the Pandemic Influenza
Preparedness Framework, and also mindful of the work being undertaken in other relevant areas and by
other United Nations entities and multilateral organizations or agencies,
12. Acknowledging that pandemic prevention, preparedness and response at all levels and in all
sectors, particularly in developing countries, require predictable, sustainable and sufficient financial,
human, logistic and technical resources, and that unequal development across countries in the promotion
of health and control of disease, especially communicable disease, is a common danger that requires
support through international collaboration,
13. Noting the adoption of the Political Declaration of the United Nations General Assembly
High-level Meeting on Pandemic Prevention, Preparedness and Response, during the 78th session of the
United Nations General Assembly, which affirms the need to prioritize equity and respect for human
rights and strengthen pandemic prevention, preparedness and response capacities,
Have agreed as follows:
Chapter I. Introduction
Article 1. Use of terms
For the purposes of the WHO Pandemic Agreement:
(a) “genetic sequences” means the order of nucleotides identified in a molecule of DNA or
RNA. They contain the genetic information that determines the biological characteristics of an
organism or a virus;
(b) “genomics” means the study of the total or part of the genetic or epigenetic sequence
information of organisms and attempts to understand the structure and function of these sequences
and downstream biological products. Genomics in health examines molecular mechanisms and
the interplay of this molecular information, health interventions and environmental factors in
disease;
(c) “infodemic” means too much information, false or misleading information, in digital and
physical environments during a disease outbreak. It causes confusion and risk-taking behaviours
that can harm health. It also leads to mistrust in health authorities and undermines public health
and social measures;
(d) “One Health approach” means an integrated, unifying approach that aims to sustainably
balance and optimize the health of people, animals and ecosystems. It recognizes that the health
of humans, domestic and wild animals, plants and the wider environment (including ecosystems)
is closely linked and interdependent. The approach mobilizes multiple sectors, disciplines and
communities at varying levels of society to work together to foster well-being and tackle threats
to health and ecosystems, while addressing the collective need for clean water, energy and air,
safe and nutritious food, taking action on climate change, and contributing to sustainable
development;
(e) “pandemic” means the global spread of a pathogen or variant that infects human
populations with limited or no immunity through sustained and high transmissibility from person
to person, overwhelming health systems with severe morbidity and high mortality and causing
A/INB/7/3
6
social and economic disruptions, all of which requires effective national and global collaboration
and coordination for its control;
(f) “pandemic-related products” means products that are needed for pandemic prevention,
preparedness and response, which may include, without limitation, diagnostics, therapeutics,
medicines, vaccines, personal protective equipment, syringes and oxygen;
(g) “Party” means a State or regional economic integration organization that has consented to
be bound by this Agreement, in accordance with its terms, and for which this Agreement is in
force;
(h) “pathogen with pandemic potential” means any pathogen that has been identified to infect
humans and that is potentially highly transmissible, capable of wide, uncontrollable spread in
human populations, and highly virulent, making it likely to cause significant morbidity and/or
mortality in humans;
(i) “persons in vulnerable situations” means individuals, groups or communities with a
disproportionate increased risk of infection, severity, disease or mortality in the context of a
pandemic, including vulnerability due to discrimination on the basis of race, colour, sex,
language, religion, political or other opinion, national or social origin, property, birth or other
status;
(j) “recipient” means receivers of WHO Pathogen Access and Benefit-Sharing (WHO PABS)
Material from the WHO coordinated laboratory network, such as manufacturers of vaccines,
diagnostics, pharmaceuticals and other products relevant to pandemic prevention, preparedness
and response, as well as biotechnology firms, research institutions and academic institutions. Any
manufacturer that enters into any contracts or formal agreements with recipients or laboratories
in the WHO coordinated network for the purpose of using WHO PABS Material on the
manufacturer’s behalf for commercialization, public use or regulatory approval of that
manufacturer’s vaccines, diagnostics or pharmaceuticals shall also be considered a recipient for
purposes of this Agreement;
(k) “universal health coverage” means that all people have access to the full range of quality
health services they need, when and where they need them, without financial hardship. It covers
the full continuum of essential health services, from health promotion to prevention, treatment,
rehabilitation and palliative care;
(l) “WHO coordinated laboratory network” means the international network of laboratories,
coordinated by WHO, that conduct year-round surveillance of pathogens with pandemic potential,
assessing the risk of an emerging pathogen with pandemic potential and assisting in pandemic
preparedness measures; and
(m) “WHO PABS Material” means a pathogen with pandemic potential, as defined herein, and
the genetic sequence data of such pathogens with pandemic potential.
Article 2. Objective and scope
1. The objective of the WHO Pandemic Agreement, guided by equity, the right to health and the
principles and approaches set forth herein, is to prevent, prepare for and respond to pandemics, with the
aim of comprehensively and effectively addressing the systemic gaps and challenges that exist in these
areas, at national, regional and international levels.
A/INB/7/3
7
2. In furtherance of its objective, the WHO Pandemic Agreement applies at all times.
Article 3. General principles and approaches
To achieve the objective of the WHO Pandemic Agreement and to implement its provisions, the
Parties will be guided, inter alia, by the general principles and approaches set forth below.
1. Respect for human rights – The implementation of this Agreement shall be with full respect for
the dignity, human rights and fundamental freedoms of persons.
2. Sovereignty – States have, in accordance with the Charter of the United Nations and the general
principles of international law, the sovereign right to legislate and to implement legislation in pursuance
of their health policies.
3. Equity – Equity is at the centre of pandemic prevention, preparedness and response, both at the
national level within States and at the international level between States. It requires, inter alia, specific
measures to protect persons in vulnerable situations. Equity includes the unhindered, fair, equitable and
timely access to safe, effective, quality and affordable pandemic-related products and services,
information, pandemic-related technologies and social protection.
4. Responsibility – Governments have a responsibility for the health of their peoples, and effective
pandemic prevention, preparedness and response require global collective action.
5. Recognition of different levels of capacity – Countries have varying levels of pandemic
prevention, preparedness and response capacities, which presents a common danger such that support
to countries with capacity needs is required, within the means and resources available.
6. Solidarity – Effective national, international, multilateral, bilateral and multisectoral
collaboration, coordination and cooperation to achieve the common interest of a safer, fairer, more
equitable and better prepared world to prevent, respond to and recover from pandemics.
7. Transparency – The effective prevention of, preparedness for and response to pandemics
depends on the transparent, open and timely sharing of, access to and disclosure of accurate information,
data and other relevant elements that may come to light, for risk assessment, prevention and control
measures, and the research and development of pandemic-related products and services, including
reports on sales revenues, prices, units sold, marketing costs and subsidies and incentives, consistent
with national, regional and international privacy and data protection rules, regulations and laws.
8. Accountability – States are accountable for strengthening and sustaining their health systems’
capacities and public health functions to provide adequate public health and social measures by adopting
and implementing legislative, executive, administrative and other measures for fair, equitable, effective
and timely pandemic prevention, preparedness and response. States are accountable to provide specific
measures to protect persons in vulnerable situations.
9. Inclusiveness – The full and active engagement with, and participation of, communities and
relevant stakeholders across all levels, consistent with relevant and applicable international and national
guidelines, rules and regulations, including those relating to conflicts of interest, is essential to mobilize
social capital, resources and adherence to public health and social measures, and to gain trust in
governments and partners supporting pandemic prevention, preparedness and response.
A/INB/7/3
8
10. Science and evidence – The best available science and evidence should inform and be the basis
for pandemic prevention, preparedness and response, as well as public health decisions and development
of plans.
11. Proportionality – Public health decisions for preventing, preparing for and responding to
pandemics should be proportionate in a manner consistent with Article 2 of the International Health
Regulations.
12. Privacy, data protection and confidentiality – Implementation of this Agreement shall respect
the right to privacy, including as such right is established under international law, and shall be consistent
with each Party’s national laws and international obligations regarding confidentiality, privacy and data
protection, as applicable.
Chapter II. The world together equitably: Achieving equity in, for and through
pandemic prevention, preparedness and response
Article 4. Pandemic prevention and public health surveillance
1. The Parties shall cooperate with one another, in bilateral, regional and multilateral settings, in the
development and strengthening of pandemic prevention and public health surveillance capacities.
2. The Parties should take actions to strengthen multisectoral, coordinated data interoperability and
support the adoption of relevant international data standards in the development of pandemic prevention
and public health surveillance capacities, with particular regard to the strengthening of developing
countries’ capacities.
3. The Parties shall cooperate, with the support of the WHO Secretariat, to strengthen and maintain
public health laboratory and diagnostic capacities, especially in respect of the capacity to perform
genetic sequencing, data science to assess the risks of detected pathogens and to safely handle samples
containing pathogens, and the use of related digital tools.
4. Each Party shall develop, strengthen, implement, periodically update and review comprehensive
multisectoral national pandemic prevention and public health surveillance plans that are consistent with
and supportive of the effective implementation of the International Health Regulations. To this end, each
Party shall, in accordance with its capabilities:
(a) develop, strengthen and maintain capacity to: (i) detect, identify and characterize pathogens
presenting significant risks; and (ii) conduct risk assessments of such pathogens and vector-borne
diseases to prevent spill-over in human and animal populations and cause serious diseases leading
to pandemic situations;
(b) strengthen efforts to ensure access to safe water, sanitation and hygiene, including in hard-
to-reach settings in the Party’s territory;
(c) ensure the implementation of effective infection prevention and control measures, applying
as far as possible the applicable international standards and guidelines;
(d) strengthen efforts to ensure the sound management of wastes from health facilities and
require health care institutions to have in place a regularly updated infection prevention and
control programme;
A/INB/7/3
9
(e) strengthen animal disease preventive measures and monitor and mitigate environmental
factors associated with the risk of zoonotic disease spill-over and spill-back;
(f) strengthen laboratory biosafety and biosecurity, including in research facilities, in order to
prevent the accidental exposure, misuse or inadvertent laboratory release of pathogens, through
biosecurity training and practices, regulating access to sensitive locations and strengthening
transportation security and cross-border transfer, in accordance with applicable rules and
standards; and
(g) take actions to prevent outbreaks due to pathogens that are resistant to antimicrobial agents,
and, in accordance with national context, develop and implement a national One Health action
plan that includes an antimicrobial resistance component.
5. Each Party shall develop, strengthen and maintain capacity to carry out integrated public health
surveillance, including in respect of infectious diseases in humans, and animals that present significant
risks of zoonotic diseases spill-over.
Article 5. One Health
1. The Parties commit to promote and implement a One Health approach for pandemic prevention,
preparedness and response that is coherent, integrated, coordinated and collaborative among all relevant
actors, with the application of, and in accordance with, national law.
2. The Parties shall promote and enhance synergies between multisectoral and transdisciplinary
collaboration at the national level and cooperation at the international level, in order to identify and
conduct risk assessments at the interface between human, animal and environment ecosystems, while
recognizing their interdependence, and with applicable sharing of the benefits, per the terms of
Article 12 herein.
3. The Parties commit to identify and address the drivers of pandemics and the emergence and re-
emergence of disease at the human-animal-environment interface through the identification and
integration of interventions into relevant pandemic prevention, preparedness plans, and, where
appropriate, according to national legislation and capacity, through the strengthening of synergies with
other relevant instruments.
4. Each Party shall, in accordance with national context and to the extent necessary, protect human,
animal and plant health by:
(a) implementing science-based actions, including but not limited to: improving infection
prevention and control measures; antimicrobial research and development; access to and
stewardship of antimicrobials; and harmonization of surveillance, in order to prevent, reduce the
risk of, and prepare for, pandemics;
(b) fostering and implementing actions at national and community levels that encompass
whole-of-government and whole-of-society approaches to control zoonotic outbreaks, including
through the engagement of communities in surveillance to identify zoonotic outbreaks;
(c) taking a One Health approach into account in order to produce science-based evidence,
including that which is related to social and behavioural sciences, and risk communication and
community engagement; and
A/INB/7/3
10
(d) promoting or establishing One Health joint training and continuing education programmes
for human, animal and environmental health workforces, needed to build complementary skills,
capacities and capabilities to prevent, detect, control and respond to pandemic health threats.
5. The Parties commit to develop, within the framework of relevant institutions, international norms
and guidelines to prevent zoonoses.
6. Pursuant to Article 21 herein, the Conference of the Parties shall develop appropriate modalities
to address the measures set forth in Articles 4 and 5 of this Agreement.
7. The Parties shall, in line with Article 16 herein, develop and implement or strengthen, as
appropriate, bilateral, regional, subregional and other multilateral channels to enhance financial and
technical support, assistance and cooperation, in particular in respect of developing countries, to
strengthen surveillance systems and laboratory capacity in respect of promoting and implementing a
One Health approach at the national level.
Article 6. Preparedness, readiness and resilience
1. Each Party shall continue to strengthen its health system, including primary health care, for
sustainable pandemic prevention, preparedness and response, taking into account the need for equity
and resilience, with a view to the progressive realization of universal health coverage.
2. Each Party shall, in accordance with applicable laws, including, where appropriate, the
International Health Regulations, adopt policies, strategies and/or measures, as appropriate, and
strengthen and reinforce public health functions for:
(a) the continued provision of quality routine and essential health services during pandemics;
(b) sustaining and strengthening the capacities of the multidisciplinary workforce needed
during interpandemic periods, and preparing for and ensuring surge capacity during pandemics;
(c) collaborative surveillance, outbreak detection, investigation and control, through
interoperable early warning and alert systems, and timely notification;
(d) multisectoral prevention of zoonoses, epidemic-prone diseases and emerging, growing or
evolving public health threats with pandemic potential, notably at the human-animal-environment
interface;
(e) the development of rehabilitation and post-pandemic health system recovery strategies;
(f) strengthening public health laboratory and diagnostic capacities, and national, regional and
global networks, through the application of standards and protocols for public health laboratory
biosafety and biosecurity;
(g) creating and maintaining up-to-date, universal, interconnected platforms and technologies
for early detection, forecasting and timely information sharing, through appropriate capacities,
including building digital health and data science capacities;
(h) creating and strengthening public health institutions at national, regional and international
levels;
A/INB/7/3
11
(i) strengthening public health emergency operations centres’ capacities during interpandemic
and pandemic periods; and
(j) strengthening infection prevention and control.
3. The Parties shall cooperate, within available means and resources, to provide financial, technical
and technological support, assistance, capacity-strengthening and cooperation, in particular in respect
of developing countries, in order to strengthen health emergency prevention, preparedness and response
and health system recovery, consistent with the goal of universal health coverage.
4. The Parties shall establish, building on existing arrangements as appropriate, genomics, risk
assessment and laboratory networks in order to conduct surveillance and sharing of emerging pathogens
with pandemic potential, pursuant to the terms and modalities established in Article 12 herein.
Article 7. Health and care workforce
1. Each Party, in line with its respective capacities, shall take the necessary steps to safeguard,
protect, invest in and sustain a skilled, trained, competent and committed health and care workforce,
with the aim of increasing and sustaining capacities for pandemic prevention, preparedness and
response, while maintaining quality essential health services and essential public health functions during
pandemics. To this end, each Party shall, in accordance with national law:
(a) strengthen, pre-, in- and post-service competency-based education and training,
deployment, remuneration, distribution and retention of the public health, health and care
workforce, including community health workers and volunteers;
(b) address gender and youth disparities and inequalities and security concerns within the
public health, health and care workforce, particularly in health emergencies, to support the
meaningful representation, engagement, participation, empowerment, safety and well-being of all
health and care workers, while addressing discrimination, stigma and inequality and eliminating
bias, including unequal remuneration, and noting that women still often face significant barriers
to reaching leadership and decision-making roles;
(c) strengthen efforts to address the safety of the health and care workforce, including by
ensuring priority access to pandemic-related products during pandemics, minimizing disruptions
to the delivery of good quality essential health services, and developing and integrating effective
measures to prevent and address violence and threats against health and care workers, their means
of transport and equipment, as well as hospitals and other medical facilities, when preventing and
responding to pandemics; and
(d) establish and maintain effective workforce planning systems to effectively and efficiently
deploy trained health and care workers during pandemics.
2. The Parties shall commit financial and technical support, assistance and cooperation, in particular
in respect of developing countries, in order to strengthen and sustain a skilled and competent public
health, health and care workforce at subnational, national and regional levels.
3. The Parties shall invest in establishing, sustaining, coordinating and mobilizing a skilled and
trained multidisciplinary global public health emergency workforce that is deployable to support Parties
upon request, based on public health need, in order to contain outbreaks and prevent the escalation of a
small-scale spread to global proportions.
A/INB/7/3
12
4. The Parties shall develop a network of training institutions, national and regional facilities, and
centres of expertise to strengthen and sustain a skilled and competent public health, health and care
workforce at subnational, national and regional levels.
Article 8. Preparedness monitoring and functional reviews
1. Each Party shall, in accordance with national laws and in the light of national context, develop
and implement comprehensive, inclusive, multisectoral, resourced national plans and strategies for
pandemic prevention, preparedness and response and health system recovery.
2. Each Party shall assess, no less than every five years, with technical support from the WHO
Secretariat upon request, the functioning and readiness of, and gaps in, its pandemic preparedness,
surveillance and multisectoral response capacity, logistics and supply chain management, and risk
assessment, and shall support the conduct of, inter alia, appropriate simulation or tabletop exercises, and
intra- and after-action reviews, based on the relevant tools and guidelines developed by WHO in
partnership with relevant organizations.
3. The Parties shall, building on existing tools, develop and implement an inclusive, transparent,
effective and efficient pandemic prevention, preparedness and response monitoring and evaluation
system.
4. The Parties shall establish, no later than 31 December 2026, a global peer review mechanism to
assess pandemic prevention, preparedness and response capacities and gaps, as well as levels of
readiness, with the aim of promoting and supporting learning among Parties, best practices, actions and
accountability, at the national, regional and global levels, to strengthen national health emergency
preparedness and readiness capacities.
Article 9. Research and development
1. The Parties shall cooperate to build, strengthen and sustain geographically diverse capacities and
institutions for research and development, particularly in developing countries, and shall promote
research collaboration and access to research through open science approaches for the rapid sharing of
information and results.
2. To this end, the Parties shall promote:
(a) sustained investment in the research and development of public health priorities, including
for pandemic-related products, aimed at improving equitable access to and delivery of such
products, and support for national and regional research institutions that can rapidly adapt and
respond to research and development needs in case of a pandemic;
(b) technology co-creation and joint venture initiatives, actively engaging the participation of
and collaboration among scientists and/or research centres, particularly from developing
countries;
(c) participation of relevant stakeholders, consistent with applicable biosafety and biosecurity
obligations, laws, regulations and guidance, to accelerate innovative research and development,
including community-led and cross-sector collaboration, for addressing emerging and
re-emerging pathogens with pandemic potential; and
A/INB/7/3
13
(d) knowledge translation and evidence-based communication tools, strategies and
partnerships relating to pandemic prevention, preparedness and response, including infodemic
management, at local, national, regional and international levels.
3. The Parties shall, in accordance with national laws and regulatory frameworks and contexts, take
steps to develop and sustain strong, resilient and appropriately resourced, national, regional and
international research capabilities. To this end, the Parties shall:
(a) increase clinical trial capacities, including by:
(i) building and maintaining a skilled research workforce and infrastructure, as
appropriate;
(ii) strengthening clinical trial policy frameworks, particularly in developing countries;
(iii) investing in the infrastructure and training of clinical research networks and the
coordination of clinical trials through existing, new or expanded clinical trial networks,
including in developing countries, to be prepared to provide timely and appropriate
responses to pandemics; and
(iv) identifying and researching supply chain needs to rapidly mount and scale research
responses during pandemic emergencies.
(b) ensure that clinical trials have equitable representation, considering racial, ethnic and
gender diversity across the life cycle, and are designed to help to address geographical,
socioeconomic and health disparities, to promote a better understanding of the safety and efficacy
of pandemic-related products for population subgroups;
(c) promote the sharing of information on national research agendas, including research and
development priorities during pandemic emergencies, capacity-building activities and best
practices on efficient and ethical clinical trials, including through the WHO Global Observatory
on Health Research and Development;
(d) strengthen international coordination and collaboration in respect of clinical trials, through
existing or new mechanisms, to support well-designed and well-implemented clinical trials;
(e) develop national policies to support the transparent, public sharing of clinical trial protocols
and results conducted either within their territories or through partnerships with other Parties,
such as through open access publications, while protecting privacy and health identifiers; and
(f) support new and existing mechanisms to facilitate the rapid reporting and interpretation of
data from clinical trials, to develop or modify, as necessary, relevant clinical trial guidelines,
including during a pandemic.
A/INB/7/3
14
4. Each Party shall, in accordance with national laws and considering the extent of public funding
provided, publish the terms of government-funded research and development agreements for pandemic-
related products, including information on:
(a) research inputs, processes and outputs, including scientific publications and data
repositories, with data shared and stored securely in alignment with findability, accessibility,
interoperability and reusability principles;
(b) the pricing of end-products, or pricing policies for end-products;
(c) licensing to enable the development, manufacturing and distribution of pandemic-related
products, especially in developing countries; and
(d) terms regarding affordable, equitable and timely access to pandemic-related products
during a pandemic.
Article 10. Sustainable production
1. The Parties, with a view to achieving a more equitable geographical distribution of the global
production of pandemic-related products, and increasing timely, fair and equitable access to safe,
effective, quality and affordable pandemic-related products, thereby reducing the potential gap between
supply and demand at the time of a pandemic, shall:
(a) take measures to identify and maintain production facilities at national and regional levels,
as well as to facilitate the production, as appropriate, and in furtherance of the provisions of
Article 13 herein, of pandemic-related products therein;
(b) take measures to identify and contract with manufacturers other than those referenced in
paragraph 1(a) of this Article, for scaling up the production of pandemic-related products, during
pandemics, in cases where the production and supply capacity of the production facilities does
not meet demand;
(c) strengthen coordination with relevant international organizations, including United Nations
entities, on issues related to public health, intellectual property and trade, including the timely
matching of supply to demand and mapping manufacturing capacities and demand;
(d) encourage entities, including manufacturers within their respective jurisdictions, in
particular those that receive significant public financing, to grant, subject to any existing licensing
restrictions, on mutually agreed terms, non-exclusive, royalty-free licences to any manufacturers,
particularly from developing countries, to use their intellectual property and other protected
substances, products, technology, know-how, information and knowledge used in the process of
pandemic-related product development and production, in particular for pre-pandemic and
pandemic diagnostics, vaccines and therapeutics for use in agreed developing countries;
(e) actively support, participate in and/or implement, as appropriate, relevant WHO
technology, skills and know-how transfer programmes and initiatives aimed at enabling
developing countries to produce pandemic-related products, in order to facilitate strategically and
geographically distributed production of pandemic-related products; and
A/INB/7/3
15
(f) support public and private sector investments aimed at creating or expanding
manufacturing facilities for pandemic-related products, especially facilities with a regional
operational scope that are based in developing countries.
2. Each Party shall initiate or strengthen, as appropriate, the conduct of disease burden studies
relevant to pathogens with pandemic potential, with a view to ensuring the sustainability of investments
in facilities for the production of vaccines and therapeutics that could support pandemic response.
3. Each Party, in addition to the undertakings in paragraph 2 of this Article, shall:
(a) encourage research and development institutes and manufacturers, in particular those
receiving significant public financing, to waive or manage, for a limited duration, royalties on the
use of their technology for the production of pandemic-related products;
(b) promote the publication, by private rights holders, of the terms of licensing agreements or
technology transfer agreements for pandemic-related products; and
(c) promote the voluntary licensing and transfer of technology and related know-how for
pandemic-related products by private rights holders with established regional or global
technology transfer hubs or other multilateral mechanisms or networks.
Article 11. Transfer of technology and know-how
1. The Parties, within a set time frame, working through the Conference of the Parties, shall
strengthen existing, and develop innovative, multilateral mechanisms, including through the pooling of
knowledge, intellectual property and data, that promote the transfer of technology and know-how for
the production of pandemic-related products, on mutually agreed terms as appropriate, to manufacturers,
particularly in developing countries.
2. The Parties shall:
(a) coordinate with, collaborate with, facilitate and incentivize the manufacturers of
pandemic-related products to transfer relevant technology and know-how to manufacturer(s) on
mutually agreed terms as appropriate, including through technology transfer hubs and product
development partnerships, and to address the need to develop new pandemic-related products in
a short time frame;
(b) make available non-exclusive licensing of government-owned technologies, on mutually
agreed terms as appropriate, for the development and manufacturing of pandemic-related
products, and publish the terms of these licences;
(c) make use of the flexibilities provided in the Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS Agreement), including those recognized in the Doha
Declaration on the TRIPS Agreement and Public Health and in Articles 27, 30 (including the
research exception and “Bolar” provision), 31 and 31bis of the TRIPS Agreement, and fully
respect the use thereof by others;
(d) collaborate to ensure equitable and affordable access to health technologies that promote
the strengthening of national health systems and mitigate social inequalities;
A/INB/7/3
16
(e) develop a database that provides the details of pandemic-related products for all known
pandemic-potential diseases, including the technological specifications and manufacturing
process documents for each product; and
(f) provide, within their capabilities, resources to support capacity-building for the
development and transfer of relevant technology, skills and know-how, and to facilitate access to
other sources of support.
3. During pandemics, each Party shall, in addition to the undertakings in paragraph 2 of this Article:
(a) commit to agree upon, within the framework of relevant institutions, time-bound waivers
of intellectual property rights to accelerate or scale up the manufacturing of pandemic-related
products to the extent necessary to increase the availability and adequacy of affordable pandemic-
related products;
(b) encourage all holders of patents related to the production of pandemic-related products to
waive or manage, as appropriate, for a limited duration, the payment of royalties by developing
country manufacturers on the use, during the pandemic, of their technology for the production of
pandemic-related products, and shall require, as appropriate, those that have received public
financing for the development of pandemic-related products to do so; and
(c) encourage manufacturers within its jurisdiction to share undisclosed information, in
accordance with paragraph 2 of Article 39 of the TRIPS Agreement, with qualified third-party
manufacturers when the withholding of such information prevents or hinders urgent manufacture
by qualified third parties of a pharmaceutical product that is necessary to respond to the pandemic.
4. The Parties shall, with a view to effective pandemic response, when engaged in bilateral or
regional trade or investment negotiations, take steps so that the negotiated provisions do not interfere
with the full use of the flexibilities provided in the TRIPS Agreement, including those recognized in the
Doha Declaration on the TRIPS Agreement and Public Health.
Article 12. Access and benefit sharing
1. The Parties hereby establish a multilateral system for access and benefit sharing, on an equal
footing, the WHO Pathogen Access and Benefit-Sharing System (WHO PABS System), to ensure rapid
and timely risk assessment and facilitate rapid and timely development of, and equitable access to,
pandemic-related products for pandemic prevention, preparedness and response.
2. The WHO PABS System shall ensure rapid, systematic and timely sharing of WHO PABS
Material, as well as, on an equal footing, timely, effective, predictable and equitable access to pandemic-
related products, and other benefits, both monetary and non-monetary, based on public health risks and
needs, to strengthen pandemic prevention, preparedness and response.
3. The Parties shall implement the WHO PABS System:
(a) in a manner to strengthen, expedite and not impede research and innovation;
(b) at all times, both during and between pandemics;
(c) in a manner to ensure mutual complementarity with the Pandemic Influenza Preparedness
Framework; and
A/INB/7/3
17
(d) with governance and review mechanisms, to be determined by the Conference of the
Parties.
4. The WHO PABS System shall have the following components:
(a) WHO PABS Materials sharing:
(i) Each Party, through its relevant public health authorities and authorized laboratories,
shall, in a rapid, systematic and timely manner: (1) provide WHO PABS Material to a
laboratory recognized or designated as part of an established WHO coordinated laboratory
network; and (2) upload the genetic sequence of such WHO PABS Material to one or more
publicly accessible database(s) of its choice, provided that the database has put in place an
appropriate arrangement in respect of WHO PABS Materials.
(ii) The WHO PABS System shall be consistent with international legal frameworks,
notably those for the collection of patient specimens, material and data, and will promote
findable, accessible, interoperable and reusable data available to all Parties.
(iii) The Parties shall develop and use a Standard Material Transfer Agreement (a PABS
SMTA), which may be concluded through electronic means, and which shall include
relevant biosafety and biosecurity rules, to be used with the transfer of WHO PABS
Materials from a laboratory recognized or designated as part of an established WHO
coordinated laboratory network to any Recipient.
(iv) Recipients of WHO PABS Material shall not seek to obtain any intellectual rights
on WHO PABS Material.
(b) PABS multilateral benefit sharing:
(i) Benefits, both monetary and non-monetary, arising from access to WHO PABS
Materials, shall be shared fairly and equitably, pursuant to a PABS SMTA, which may be
concluded through electronic means.
(ii) The PABS SMTAs shall include, but not be limited to, the following monetary and
non-monetary benefit-sharing obligations:
(a) in the event of a pandemic, real-time access by WHO to a minimum of 20%
(10% as a donation and 10% at affordable prices to WHO) of the production of safe,
efficacious and effective pandemic-related products for distribution based on public
health risks and needs, with the understanding that each Party that has manufacturing
facilities that produce pandemic-related products in its jurisdiction shall take all
necessary steps to facilitate the export of such pandemic-related products, in
accordance with timetables to be agreed between WHO and manufacturers; and
(b) on an annual basis, contributions from Recipients, based on their nature and
capacity, to the capacity development fund of the sustainable funding mechanism
established in Article 20 herein.
A/INB/7/3
18
(c) The Parties shall also consider additional benefit-sharing options, including:
(i) encouraging manufacturers from developed countries to collaborate with
manufacturers from developing countries through WHO initiatives to transfer technology
and know-how and strengthen capacities for the timely scale-up of production of pandemic-
related products;
(ii) tiered-pricing or other cost-related arrangements, such as no loss/no profit loss
arrangements, for purchase of pandemic-related products, that consider the income level of
countries; and
(iii) encouraging of laboratories in the WHO coordinated laboratory network to actively
seek the participation of scientists from developing countries in scientific projects
associated with research on WHO PABS Materials.
5. In the event that pandemic-related products are produced by a manufacturer that does not have a
PABS SMTA under the WHO PABS System, it shall be understood that the production of
pandemic-related products requiring the use of WHO PABS Materials, implies the use of the WHO
PABS System. Accordingly, each Party, in respect of such a manufacturer operating within its
jurisdiction, shall take all appropriate steps, in accordance with its relevant laws and circumstances, to
require such a manufacturer to provide benefits in accordance with paragraph 4(b)(ii) of this Article.
6. The Parties shall develop a mechanism to ensure the fair and equitable allocation of pandemic-
related products, based on public health risks and needs.
7. The Parties shall ensure that all components of the WHO PABS System are operational no later
than 31 May 2025. The Parties shall review the operation and functioning of the WHO PABS System
every five years.
8. The Parties shall ensure that the WHO PABS System is consistent with, supportive of and does
not run counter to the objectives of the Convention on Biological Diversity and the Nagoya Protocol on
Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their
Utilization thereto. The WHO PABS System will provide certainty and legal clarity to the providers and
users of WHO PABS Materials. The WHO PABS System shall be recognized as a specialized
international access and benefit-sharing instrument within the meaning of paragraph 4 of Article 4 of
the Nagoya Protocol.
Article 13. Global Supply Chain and Logistics Network
1. The WHO Global Supply Chain and Logistics Network (the WHO SCL Network) is hereby
established. The WHO SCL Network will operate within the framework of WHO, in partnership and
collaboration with relevant international, regional and other organizations, and be guided by equity and
public health needs, paying particular attention to the needs of developing country Parties.
2. The Conference of the Parties shall develop guidelines on modalities and collaboration for the
WHO SCL Network, which shall be aimed at ensuring close consultation among Parties and that
functions are discharged by the organizations best placed to perform them.
A/INB/7/3
19
3. The Parties shall support the WHO SCL Network’s development and operationalization and
participate in the WHO SCL Network, including through sustaining it at all times. The terms of the
WHO SCL Network shall include:
(a) estimating, or, where possible, determining, the most likely types and size/volume of
products needed for robust pandemic prevention, preparedness and response, including the costs
and logistics for establishing and maintaining strategic stockpiles of such products;
(b) assessing the anticipated demand for, mapping the sources of and maintaining a dashboard
of manufacturers and suppliers, including surge capacities and relevant necessary raw materials,
for the sustainable production of pandemic-related products;
(c) identifying the most efficient multilateral and regional purchasing mechanisms, including
pooled mechanisms;
(d) working with national authorities to establish and maintain national and/or regional
stockpiles of various pandemic response-related products, as well as maintaining the relevant
logistic capacities and assessing them at regular intervals, and specifying the criteria to ensure
that stockpiling is used only to address public health needs;
(e) facilitating the negotiation and agreement of advance purchase commitments and
procurement contracts for pandemic-related products;
(f) promoting transparency in cost, pricing and all other relevant contractual terms along the
supply chain;
(g) coordinating to avoid competition for resources among procuring entities, including
regional organizations and/or mechanisms;
(h) mapping existing, and identifying needed, delivery and distribution options;
(i) establishing or operationalizing, as appropriate, international or regional stockpiles,
consolidation hubs and staging areas;
(j) assisting buying countries in meeting the logistic requirements for the utilization of specific
pandemic-related products; and
(k) facilitating or, as necessary, organizing the efficient delivery and appropriate utilization of
pandemic-related products in beneficiary countries or in humanitarian settings.
4. Each Party shall take appropriate measures to reduce waste of pandemic-related products,
including through the exchange and/or donation of products in order to maximize their use, while taking
account of the needs of recipient countries.
5. Each Party shall, at the earliest reasonable opportunity and in accordance with applicable laws,
make publicly available online the terms of government-funded purchase agreements for
pandemic-related products in those instances in which the Party is directly entering into such purchase
agreements.
A/INB/7/3
20
6. Each Party shall, in its government-funded purchase agreements for pandemic-related products,
to the fullest extent possible and in accordance with applicable laws, exclude confidentiality provisions
that serve to limit the disclosure of terms and conditions.
7. The Parties recognize that any emergency trade measures in the event of a pandemic shall be
targeted, proportionate, transparent and temporary, and do not create unnecessary barriers to trade or
unnecessary disruptions in supply chains.
8. The Parties shall commit to ensure rapid and unimpeded access of humanitarian relief personnel,
as well as their means of transport, supplies and equipment, in accordance with international
humanitarian law, and to respect the principles of humanity, neutrality, impartiality and independence
for the provision of humanitarian assistance.
9. The Parties shall enable inclusive, equitable and effective cooperation and participation, and shall
take all appropriate measures to undertake the foregoing no later than 31 May 2025.
Article 14. Regulatory strengthening
1. The Parties shall strengthen their national and regional regulatory authorities, including through
technical assistance, with the aim of expediting regulatory approvals and authorizations and ensuring
the quality, safety and efficacy of pandemic-related products.
2. The Parties shall align and, where possible, harmonize technical and regulatory requirements and
procedures, in accordance with applicable international standards, guidance and protocols, including
those covering regulatory reliance and mutual recognition, and share relevant information and
assessments concerning the quality, safety and efficacy of pandemic-related products with other Parties.
3. The Parties shall, as appropriate, monitor, regulate and strengthen rapid alert systems against
substandard and falsified pandemic-related products.
4. Each Party shall, in accordance with relevant laws, publicly disclose information on national and,
if applicable, regional processes for authorizing or approving use of pandemic-related products, and any
additional relevant regulatory pathways for such pandemic-related products that may be activated during
a pandemic to increase efficiency, and update such information in a timely manner.
5. Each Party shall take steps to ensure that it has the legal, administrative and financial frameworks
in place to support emergency regulatory approvals for the effective and timely regulatory approval of
pandemic-related products during a pandemic.
6. Each Party shall, in accordance with relevant laws, encourage manufacturers to generate relevant
data, contribute to the development of common technical documents, and diligently pursue regulatory
authorizations and/or approvals of pandemic-related products with WHO listed authorities, other
priority authorities and WHO.
Article 15. Compensation and liability management
1. Each Party shall develop national strategies for managing liability risks in its territory regarding
the manufacturing, distribution, administration and use of novel vaccines developed in response to
pandemics. Strategies may include, inter alia, the development of model contract provisions, vaccine
injury compensation mechanisms, insurance mechanisms, policy frameworks and principles for the
A/INB/7/3
21
negotiation of procurement agreements and/or the donation of novel vaccines developed in response to
pandemics, and building expertise for contract negotiations in this matter.
2. The Conference of the Parties shall establish, within two years of the entry into force of the WHO
Pandemic Agreement, using existing relevant models as a reference, no-fault vaccine injury
compensation mechanism(s), with the aim of promoting access to financial remedy for individuals
experiencing serious adverse events resulting from a pandemic vaccine, as well as more generally
promoting pandemic vaccine acceptance. The Conference of the Parties shall further develop the
mechanism(s), which may be regional and/or international, including strategies for funding the
mechanism(s), through the modalities provided for in Article 20 herein.
3. Each Party shall endeavour to ensure that, in contracts for the supply or purchase of novel
pandemic vaccines, buyer/recipient indemnity clauses, if any, are exceptionally provided and are time-
bound.
Article 16. International collaboration and cooperation
1. The Parties shall collaborate and cooperate with competent international and regional
intergovernmental organizations and other bodies, as well as among themselves, in the formulation of
cost-effective measures, procedures and guidelines for pandemic prevention, preparedness and response.
2. The Parties shall:
(a) promote global, regional and national political commitment, coordination and leadership
for pandemic prevention, preparedness and response;
(b) support mechanisms that ensure that policy decisions are science- and evidence-based;
(c) develop, as necessary, and implement policies that respect, protect and fulfil the human
rights of all people;
(d) promote equitable representation on the basis of gender, geographical and socioeconomic
status, as well as the equal and meaningful participation of young people and women;
(e) assist developing countries through multilateral and bilateral partnerships that focus on
developing capacities for effectively addressing health needs for pandemic prevention,
preparedness and response in line with the provisions set forth in Article 19 herein; and
(f) encourage ceasefires in affected countries during pandemics to promote global cooperation
against common global threats.
Article 17. Whole-of-government and whole-of-society approaches at the national level
1. The Parties are encouraged to adopt whole-of-government and whole-of-society approaches,
including to empower and ensure community ownership of, and contribution to, community readiness
for and resilience to pandemic prevention, preparedness and response.
2. Each Party shall, in keeping with national capacities, establish, implement and adequately finance
an effective national coordinating multisectoral mechanism.
A/INB/7/3
22
3. Each Party shall, in accordance with national context, promote the effective and meaningful
engagement of communities, civil society and other relevant stakeholders, including the private sector,
as part of a whole-of-society approach in decision-making, implementation, monitoring and evaluation,
and shall also provide effective feedback opportunities.
4. Each Party shall develop, in accordance with national context, comprehensive national pandemic
prevention, preparedness and response plans pre-, post- and interpandemic that, inter alia:
(a) identify and prioritize populations for access to pandemic-related products and health
services;
(b) support the timely and scalable mobilization of the multidisciplinary surge capacity of
human and financial resources, and facilitate the timely allocation of resources to the frontline
pandemic response;
(c) review the status of stockpiles and the surge capacity of essential public health and clinical
resources, and surge capacity in the production of pandemic-related products;
(d) facilitate the rapid and equitable restoration of public health capacities and routine and
essential health services following a pandemic; and
(e) promote collaboration with relevant stakeholders, including the private sector and civil
society.
5. Each Party, based on national capacities, shall take the necessary steps to address the social,
environmental and economic determinants of health, and the vulnerability conditions that contribute to
the emergence and spread of pandemics, and shall prevent or mitigate the socioeconomic impacts of
pandemics.
6. Each Party shall take appropriate measures to strengthen national public health and social policies
to facilitate a rapid, resilient response to pandemics, especially for persons in vulnerable situations,
including by mobilizing social capital in communities for mutual support.
Article 18. Communication and public awareness
1. The Parties shall strengthen science, public health and pandemic literacy in the population, as
well as access to information on pandemics and their effects and drivers, and combat false, misleading,
misinformation or disinformation, including through effective international collaboration and
cooperation as referred to in Article 16 herein.
2. The Parties shall, as appropriate, conduct research and inform policies on factors that hinder
adherence to public health and social measures in a pandemic and trust in science and public health
institutions.
3. The Parties shall promote and apply a science- and evidence-informed approach to effective and
timely risk assessment and public communication.
Article 19. Implementation capacities and support
1. The Parties shall cooperate, directly or through competent international bodies, to strengthen their
capacity to fulfil the obligations arising from this Agreement, taking into account especially the needs
A/INB/7/3
23
of developing country Parties. Such cooperation shall promote the transfer of technical, scientific and
legal expertise and technology, as mutually agreed, to establish and strengthen the sustainable pandemic
prevention, preparedness and response capacities of all Parties.
2. Each Party shall, within the means and resources at their disposal, cooperate to raise financial
resources for the effective implementation of the WHO Pandemic Agreement through bilateral and
multilateral funding mechanisms.
3. The Parties shall give particular consideration to the specific needs and special circumstances of
developing country Parties for financial and technical assistance to support the implementation of this
Agreement.
4. The Parties shall, where a Party lacks the necessary capacity to implement specific provision(s)
of this Agreement, work together to identify the most relevant partner(s) that can support the
development of such capacities, and shall cooperate to ensure that the mechanism(s) identified in
Article 20 herein provides the necessary financial resources.
Article 20. Financing
1. The Parties commit to sustainable financing for strengthening pandemic prevention, preparedness
and response. In this regard, each Party, within the means and resources at its disposal, shall:
(a) cooperate with other Parties, as appropriate, to raise sustainable financial resources for the
effective implementation of this Agreement through bilateral and multilateral, regional or
subregional funding mechanisms;
(b) plan and provide adequate financial support, in line with national fiscal capacities,
for: (i) strengthening and sustaining capacities for pandemic prevention, preparedness and
response; (ii) implementing national plans, programmes and priorities; and (iii) strengthening
health systems and the progressive realization of universal health coverage for pandemic
prevention, preparedness and response;
(c) prioritize and increase or maintain, including through greater collaboration between the
health, finance and private sectors, as appropriate, domestic funding for pandemic prevention,
preparedness and response;
(d) mobilize financial resources for international cooperation and assistance in respect of
pandemic prevention, preparedness and response, in accordance with its capacities and based on
the principle of solidarity, particularly for developing countries, including through international
organizations and existing and new mechanisms; and
(e) provide support and assistance to other Parties, upon request, to facilitate the containment
of spill-over at the source.
2. A sustainable funding mechanism shall be established by the Conference of the Parties no later
than 31 December 2026. The mechanism shall ensure the provision of adequate, accessible, new and
additional and predictable financial resources, and shall include the following:
(a) A capacity development fund that shall be resourced, inter alia, through the following:
(i) annual monetary contributions from Parties to the WHO Pandemic Agreement;
A/INB/7/3
24
(ii) monetary contributions from recipients pursuant to Article 12 herein; and
(iii) voluntary monetary contributions from Parties to the WHO Pandemic Agreement.
(b) An endowment for pandemic prevention, preparedness and response, resourced, inter alia,
through the following:
(i) voluntary monetary contributions from all relevant sectors that benefit from
international work to strengthen pandemic prevention, preparedness and response; and
(ii) donations from philanthropic organizations and foundations, and other voluntary
monetary contributions.
(c) The funding mechanism will provide resources to assist Parties, in particular developing
countries, in meeting their obligations under the WHO Pandemic Agreement and related activities
for pandemic prevention, preparedness and response. The funding mechanism will contribute to
funding support of the Secretariat of the WHO Pandemic Agreement.
(d) For the purposes of this Agreement, the mechanism shall function under the authority of
the Conference of the Parties, and shall be accountable thereto. The Conference of the Parties
shall further define and provide guidance on overall strategies, policies, programme priorities and
eligibility for access to and utilization of financial resources, including in respect of the
compensation mechanism(s) referred to in Article 15 herein, and shall also monitor outcomes and
address the operation and resourcing of the funding mechanism, with due regard to the avoidance
of conflicts of interest.
3. The Parties represented in relevant regional and international intergovernmental organizations
and financial and development institutions shall encourage, as appropriate, these entities to provide
additional financial assistance for developing country Parties to support them in meeting their
obligations under the WHO Pandemic Agreement, without limiting their participation in or membership
of these organizations.
Chapter III. Institutional arrangements and final provisions
Article 21. Conference of the Parties
1. A Conference of the Parties is hereby established. The Conference of the Parties shall be
comprised of delegates representing the Parties to the WHO Pandemic Agreement. Only delegates
representing Parties will participate in any of the decision-making of the Conference of the Parties. The
Conference of the Parties shall establish the criteria for the participation of observers at its proceedings.
2. With the aim of promoting the coherence of the Conference of the Parties and the Health
Assembly, as well as coherence in respect of relevant instruments and mechanisms within the framework
of the World Health Organization, the Conference of the Parties shall operate in coordination with the
Health Assembly. In particular, the Conference of the Parties shall hold its regular sessions immediately
before or after regular sessions of the Health Assembly, and in the same location and venue as the Health
Assembly, where feasible.
3. The first session of the Conference of the Parties shall be convened by the World Health
Organization not later than one year after the entry into force of the WHO Pandemic Agreement.
A/INB/7/3
25
4. Following the first session of the Conference of the Parties:
(a) subsequent regular sessions of the Conference of the Parties shall be held annually; and
(b) extraordinary sessions of the Conference of the Parties shall be held at such other times,
without reference to the regular sessions of the Health Assembly, as may be deemed necessary
by the Conference of the Parties, or at the written request of any Party, provided that, within
six months of the request being communicated to them by the Secretariat, it is supported by at
least one third of the Parties.
5. The Conference of the Parties shall adopt by consensus its Rules of Procedure at its first session.
6. The Conference of the Parties shall by consensus adopt financial rules for itself as well as
governing the funding of any subsidiary bodies of the Conference of the Parties that are or may be
established, as well as financial provisions governing the functioning of the Secretariat. It shall also
adopt a biennial budget.
7. The Conference of the Parties shall keep under regular review the implementation of the WHO
Pandemic Agreement and take the decisions necessary to promote its effective implementation, and may
adopt amendments, annexes and protocols to the WHO Pandemic Agreement, in accordance with
Articles 28, 29 and 30 herein. To this end, it shall:
(a) consider reports submitted by the Parties in accordance with Article 23 herein and adopt
regular reports on the implementation of the WHO Pandemic Agreement;
(b) oversee any subsidiary bodies, including by establishing their rules of procedure and
working modalities;
(c) promote and facilitate the mobilization of financial resources for the implementation of the
WHO Pandemic Agreement, in accordance with Article 20 herein;
(d) request, where appropriate, the services and cooperation of, and information provided by,
competent and relevant organizations and bodies of the United Nations system and other
international and regional intergovernmental organizations and nongovernmental organizations
and bodies as a means of strengthening the implementation of the WHO Pandemic Agreement;
and
(e) consider other action, as appropriate, for the achievement of the objective of the WHO
Pandemic Agreement in the light of experience gained in its implementation.
8. The Conference of the Parties shall keep under regular review, every three years, the
implementation and outcome of the WHO Pandemic Agreement and any related legal instruments that
the Conference of the Parties may adopt, and shall make the decisions necessary to promote the effective
implementation of the WHO Pandemic Agreement.
9. The Conference of the Parties shall establish subsidiary bodies to carry out the work of the
Conference of the Parties, as it deems necessary, on terms and modalities to be defined by the
Conference of the Parties. Such subsidiary bodies may include, without limitation, an Implementation
and Compliance Committee, a panel of experts to provide scientific advice and a WHO PABS System
Expert Advisory Group.
A/INB/7/3
26
Article 22. Right to vote
1. Each Party to the WHO Pandemic Agreement shall have one vote in the Conference of the Parties,
except as provided for in paragraph 2 of this Article.
2. Regional economic integration organizations, in matters within their competence, shall exercise
their right to vote with a number of votes equal to the number of their Member States that are Parties to
the WHO Pandemic Agreement, duly accredited and present during the voting. Such an organization
shall not exercise its right to vote if any of its Member States exercises its right, and vice versa.
Article 23. Reports to the Conference of the Parties
1. Each Party shall submit to the Conference of the Parties periodic reports on its implementation of
the WHO Pandemic Agreement, which shall include the following:
(a) information on good practices, legislative, executive, administrative or other measures
taken to implement the WHO Pandemic Agreement;
(b) information on any constraints or difficulties encountered in the implementation of the
WHO Pandemic Agreement and on the measures taken or under consideration to overcome them;
(c) information on implementation support received under the WHO Pandemic Agreement;
and
(d) other information as required by specific provisions of the WHO Pandemic Agreement.
2. The frequency, conditions and format of the reports, including periodic reports, submitted by the
Parties shall be determined by the Conference of the Parties at its first session, with the aim of facilitating
reporting by the Parties and avoiding duplications. These reports shall be drawn up in a clear, transparent
and exhaustive manner, without prejudice to respect for applicable rules on confidentiality, privacy and
data protection.
3. The Conference of the Parties shall adopt appropriate measures to assist Parties, upon request, in
meeting their obligations under this Article, paying particular attention to the needs of developing
country Parties.
4. The periodic reports submitted by the Parties shall be made publicly available online by the
Secretariat.
Article 24. Secretariat
1. A Secretariat for the WHO Pandemic Agreement is hereby established. Secretariat functions for
the WHO Pandemic Agreement shall be provided by the World Health Organization.
2. Secretariat functions shall be to:
(a) provide administrative and logistic support to the Conference of the Parties for the purpose
of the implementation of this Agreement, and to make arrangements for the sessions of the
Conference of the Parties and any subsidiary bodies and to provide them with services, as
required;
A/INB/7/3
27
(b) transmit reports and other relevant information regarding the implementation of this
Agreement received by it pursuant to this Agreement;
(c) provide support to the Parties, upon request, particularly developing country Parties and
Parties with economies in transition, in implementing the WHO Pandemic Agreement, including
the compilation and communication of information required in accordance with the provisions of
the WHO Pandemic Agreement or pursuant to requests of the Conference of the Parties;
(d) prepare reports on its activities under the WHO Pandemic Agreement under the guidance
of the Conference of the Parties, and to submit them to the Conference of the Parties;
(e) ensure, under the guidance of the Conference of the Parties, the necessary coordination
with competent international and regional intergovernmental organizations and other bodies;
(f) enter, under the guidance of the Conference of the Parties, into such administrative or
contractual arrangements as may be required for the effective discharge of its functions;
(g) cooperate and coordinate with other United Nations entities in related areas; and
(h) perform other secretariat functions specified by the WHO Pandemic Agreement and such
other functions as may be determined by the Conference of the Parties.
Article 25. Relationship with other international agreements and instruments
1. The implementation of the WHO Pandemic Agreement shall be guided by the Charter of the
United Nations and the Constitution of the World Health Organization.
2. The Parties recognize that the WHO Pandemic Agreement and other relevant international
instruments, including the International Health Regulations, should be interpreted so as to be
complementary and compatible. The provisions of the WHO Pandemic Agreement shall not affect the
rights and obligations of any Party under other existing international instruments.
3. The provisions of the WHO Pandemic Agreement shall in no way affect the ability of Parties to
enter into bilateral or multilateral agreements, including regional or subregional agreements, on issues
relevant or additional to the WHO Pandemic Agreement, provided that such agreements are compatible
with their obligations under the WHO Pandemic Agreement. The Parties concerned shall communicate
such agreements to the Conference of the Parties, through the Secretariat.
Article 26. Reservations
No reservations may be made to the WHO Pandemic Agreement.
Article 27. Withdrawal
1. At any time after two years from the date on which the WHO Pandemic Agreement has entered
into force for a Party, that Party may withdraw from the WHO Pandemic Agreement by giving written
notification to the Depositary.
2. Any such withdrawal shall take effect upon expiry of one year from the date of receipt by the
Depositary of the notification of withdrawal, or on such later date as may be specified in the notification
of withdrawal.
A/INB/7/3
28
3. Any Party that withdraws from the WHO Pandemic Agreement shall not be considered as having
also withdrawn from any protocol to which it is a Party, or from any related instrument, unless such a
Party formally withdraws from such other instruments and does so in accordance with the relevant terms,
if any, thereof.
Article 28. Amendments
1. Any Party may propose amendments to the WHO Pandemic Agreement. Such amendments shall
be considered by the Conference of the Parties.
2. Amendments to the WHO Pandemic Agreement shall be adopted by the Conference of the Parties.
The text of any proposed amendment to the WHO Pandemic Agreement shall be communicated to the
Parties by the Secretariat at least six months before the session at which it is proposed for adoption. The
Secretariat shall also communicate proposed amendments to the signatories of the WHO Pandemic
Agreement and, for information, to the Depositary.
3. The Parties shall make every effort to adopt any proposed amendment to the WHO Pandemic
Agreement by consensus. If all efforts at consensus have been exhausted and no agreement has been
reached, the amendment shall as a last resort be adopted by a three-quarters majority vote of the Parties
present and voting at the session. For the purposes of this Article, Parties present and voting means
Parties present and casting an affirmative or negative vote. Any adopted amendment shall be
communicated by the Secretariat to the Depositary, who shall circulate it to all Parties for acceptance.
4. Instruments of acceptance in respect of an amendment shall be deposited with the Depositary. An
amendment adopted in accordance with paragraph 3 of this Article shall enter into force, for those Parties
having accepted it, on the ninetieth day after the date of receipt by the Depositary of an instrument of
acceptance by at least two thirds of the Parties to the WHO Pandemic Agreement.
5. The amendment shall enter into force for any other Party on the ninetieth day after the date on
which that Party deposits with the Depositary its instrument of acceptance of the said amendment.
Article 29. Annexes
1. Annexes to the WHO Pandemic Agreement and amendments thereto shall be proposed, adopted
and shall enter into force in accordance with the procedure set forth in Article 28 herein.
2. Annexes to the WHO Pandemic Agreement shall form an integral part thereof and, unless
otherwise expressly provided, a reference to the WHO Pandemic Agreement constitutes at the same
time a reference to any annexes thereto.
3. Annexes shall be restricted to lists, forms and any other descriptive material relating to procedural,
scientific, technical or administrative matters, and shall not be substantive in nature.
Article 30. Protocols
1. Any Party may propose protocols to the WHO Pandemic Agreement. Such proposals will be
considered by the Conference of the Parties.
A/INB/7/3
29
2. The Conference of the Parties may adopt protocols to the WHO Pandemic Agreement. In adopting
these protocols, every effort shall be made to reach consensus. If all efforts at consensus have been
exhausted and no agreement has been reached, the protocol shall as a last resort be adopted by a
three-quarters majority vote of the Parties present and voting at the session. For the purposes of this
Article, Parties present and voting means Parties present and casting an affirmative or negative vote. In
the event that a protocol is proposed for adoption under Article 21 of the Constitution of the World
Health Organization, it shall further be considered for adoption by the Health Assembly.
3. The text of any proposed protocol shall be communicated to the Parties by the Secretariat at least
six months before the session at which it is proposed for adoption.
4. States that are not Parties to the WHO Pandemic Agreement may be parties to a protocol thereof,
provided the protocol so provides.
5. Any protocol to the WHO Pandemic Agreement shall be binding only on the parties to the
protocol in question. Only parties to a protocol may take decisions on matters exclusively relating to the
protocol in question.
6. The requirements for entry into force of any protocol shall be established by that instrument.
Article 31. Signature
The WHO Pandemic Agreement shall be open for signature by all Members of the World Health
Organization, by States that are not Members of the World Health Organization but are member or
non-member observer states of the United Nations, and by regional economic integration organizations.
The WHO Pandemic Agreement shall be open for signature at the World Health Organization
headquarters in Geneva, immediately following its adoption by the World Health Assembly at the
Seventy-seventh World Health Assembly, from XX [May] 2024 to XX [June] 2024, and thereafter at
United Nations Headquarters in New York, from XX [June] 2024 to XX [June] 2025.
Article 32. Ratification, acceptance, approval, formal confirmation or accession
1. The WHO Pandemic Agreement shall be subject to ratification, acceptance, approval or accession
by States and to formal confirmation or accession by regional economic integration organizations. The
WHO Pandemic Agreement shall be open for accession from the day after the date on which the WHO
Pandemic Agreement is closed for signature. Instruments of ratification, acceptance, approval, formal
confirmation or accession shall be deposited with the Depositary.
2. Any regional economic integration organization that becomes a Party to the WHO Pandemic
Agreement without any of its Member States being a Party shall be bound by all the obligations under
the WHO Pandemic Agreement. In the case of those regional economic integration organizations for
which one or more of its Member States is a Party to the WHO Pandemic Agreement, the regional
economic integration organization and its Member States shall decide on their respective responsibilities
for the performance of their obligations under the WHO Pandemic Agreement. In such cases, the
regional economic integration organization and its Member States shall not be entitled to exercise rights
under the WHO Pandemic Agreement concurrently.
3. Regional economic integration organizations shall, in their instruments relating to formal
confirmation or in their instruments of accession, declare the extent of their competence with respect to
the matters governed by the WHO Pandemic Agreement. These organizations shall also inform the
Depositary, who shall in turn inform the Parties, of any substantial modification in the extent of their
competence.
A/INB/7/3
30
Article 33. Entry into force
1. The WHO Pandemic Agreement shall enter into force on the thirtieth day following the date of
deposit of the fortieth instrument of ratification, acceptance, approval, formal confirmation or accession
with the Depositary.
2. For each State that ratifies, accepts or approves the WHO Pandemic Agreement or accedes thereto
after the conditions set forth in paragraph 1 of this Article for entry into force have been fulfilled, the
WHO Pandemic Agreement shall enter into force on the thirtieth day following the date of deposit of its
instrument of ratification, acceptance, approval or accession.
3. For each regional economic integration organization depositing an instrument of formal
confirmation or an instrument of accession after the conditions set forth in paragraph 1 of this Article
for entry into force have been fulfilled, the WHO Pandemic Agreement shall enter into force on the
thirtieth day following the date of deposit of its instrument of formal confirmation or of accession.
4. For the purposes of this Article, any instrument deposited by a regional economic integration
organization shall not be counted as additional to those deposited by Member States of that regional
economic integration organization.
Article 34. Settlement of disputes
1. In the event of a dispute between two or more Parties concerning the interpretation or application
of the WHO Pandemic Agreement, the Parties concerned shall seek through diplomatic channels a
settlement of the dispute through negotiation or any other peaceful means of their own choice, including
good offices, mediation or conciliation. Failure to reach a solution by good offices, mediation or
conciliation shall not absolve the parties to the dispute from the responsibility of continuing to seek to
resolve it.
2. When ratifying, accepting, approving, formally confirming or acceding to the WHO Pandemic
Agreement, or at any time thereafter, a Party which is not a regional economic integration organization
may declare in writing to the Depositary that, for a dispute not resolved in accordance with paragraph 1
of this Article, it accepts, as compulsory ipso facto and without special agreement, in relation to any
Party accepting the same obligation: (a) submission of the dispute to the International Court of Justice;
and/or (b) ad hoc arbitration in accordance with procedures to be adopted by consensus by the
Conference of the Parties. A Party which is a regional economic integration organization may make a
declaration with like effect in relation to arbitration in accordance with the procedures referred to in
paragraph 2(b) of this Article.
3. The provisions of this Article shall apply with respect to any protocol as between the parties to
the protocol, unless otherwise provided therein.
Article 35. Depositary
The Secretary-General of the United Nations shall be the Depositary of this Agreement and
amendments thereto and of any protocols and annexes adopted in accordance with the terms of this
Agreement.
Article 36. Authentic texts
The original of this Agreement, of which the Arabic, Chinese, English, French, Russian and
Spanish texts are equally authentic, shall be deposited with the Secretary-General of the United Nations.
= = =

パンデミックの予防、備え、対応に関するWHO条約、 協定、またはその他の国際 文書の起草と交渉を目的とした政府間
交渉機関の第9回会合が再開 A/INB/9/3 Rev.1 暫定議題項目2 2024年4月22日 WHOパンデミックに対する提案契約 A/INB/9/3 Rev.1
https://123210.net/wordpress/tatenaoshi/wp-content/uploads/sites/3/2024/04/【パンデミック条約-案_240422版】A_inb9_3Rev1-en【和訳トライ】A.pdf

WHO英語原文サイト
https://apps.who.int/gb/inb/e/e_inb-9-resumed-session.html

英語原文pdf
https://apps.who.int/gb/inb/pdf_files/inb9/A_inb9_3Rev1-en.pdf

https://www.who.int/teams/ihr/working-group-on-amendments-to-the-international-health-regulations-%282005%29

Eighth meeting of the Working Group on Amendments to the International Health Regulations (2005)
https://www.who.int/news-room/events/detail/2024/04/22/default-calendar/eighth-meeting-of-the-working-group-on-amendments-to-the-international-health-regulations-(2005)

International Health Regulations (2005) (IHR).

アジェンダ

proposed Bureau’s text.
https://apps.who.int/gb/wgihr/pdf_files/wgihr8/WGIHR8_Proposed_Bureau_text-en.pdf

和訳（機械翻訳）
https://123210.net/wordpress/tatenaoshi/wp-content/uploads/sites/3/2024/04/【パンデミック条約-IHR改定案】WGIHR8_Proposed_Bureau_text-en【和訳トライ】A.pdf

改定前のバージョン
https://123210.net/wordpress/tatenaoshi/wp-content/uploads/sites/3/2024/03/【パンデミック改正案-240314】A_inb9_3-en.cvx_.pdf

https://www-rumormillnews-com.translate.goog/cgi-bin/forum.cgi?read=239438&_x_tr_sl=auto&_x_tr_tl=ja&_x_tr_hl=ja&_x_tr_pto=wapp

(真剣に) 嘘をついているのは誰ですか: 国際保健規則条約の改正案を拒否してください

投稿者:ナマステ[電子メールを送信]
日付: 2024 年 4 月 22 日月曜日 07:21:00
www.rumormill.news/239438

遠くまで、そして広く共有

https://jamesroguski.substack.com/p/i-hold-these-truths-to-be-self-identify

国際保健規則の改正は、あなたが信じ込まされているようなものではありません。気を散らさないでください。集中力を維持しましょう。これらの修正案は悪質であり、拒否される必要があります。

ジェームス・ログスキー
4月22日

1年以上の秘密保持を経て、国際保健規則改正作業部会（WGIHR）はついに改正案の公式更新草案を発表した。

最新の提案は、対処すべき問題のいずれにもまったく対処できていません。

WHOがこれらの修正案をあたかも何らかの形で役立つかのように採択することを許可するのは、非常に見当違いです。

WHOの交渉が国家主権への攻撃であるという現在進行中の主張（以下にリストされているとおり）は、赤ニシンです。

「WHOの交渉は国家主権に対する攻撃ではない。

WHOの交渉は義務やロックダウンに関するものではない。

WHOの交渉は医師と患者の関係を掌握しようとするものではない。」

国際保健規則の改正案について知っていると思っていることはすべて忘れて、あたかも初めてその改正について学ぶかのように以下の文書を読むことを強くお勧めします。

https://apps.who.int/gb/wgihr/pdf_files/wgihr8/WGIHR8_Proposed_Bureau_text-en.pdf

https://genkimaru1.livedoor.blog/archives/2295124.html

さてはてメモ帳

プランデミック：ざっと振り返り用記事目録

さてはてメモ帳さんのサイトより
http://glassbead.blog.shinobi.jp/medical%20tyranny/documents%20listed
＜転載開始＞

動かぬ証拠！ロックフェラーの関係者がNWO計画を1969年に明らかにしていた　by Henry Makow Ph.D.
WHOは1974年から人々を永久的に不妊にするようなワクチンの開発に取り組んできました：COVID-19候補ワクチンの草案展望　WHO
邪悪な場所－ジョージア・ガイドストーン　By Vigilant　＋　薔薇の棘？

コロナウイルスパンデミックの時代にジョージアのガイドストーンに注目が向かっている　Niamh Harris

ジャック・アタリは1981年に詐欺デミックとジェノサイドを予言していた　By RM

ジャック・アタリ：NOW暴政の青写真　Ruby Eden　(Excerpts by henrymakow.com)

コロナウイルスは1981年の小説で不気味に予測されていた　By Vigilant Citizen

予測プログラミング？イスラエルの出版社は何年も前からCOVIDに似たパンデミックについて書いている　by Raul Diego　（1994）

ゲイリー・D・バーネット：Covid「ワクチン」バイオテロは数十年前から計画されていた　２

グレート・リセット高性能大型爆弾：9/11の2ヶ月後、慈善活動のカーネギーメダル賞で一緒にいるアンソニー・ファウチ、ジョージ・ソロス、ビル・ゲイツ・シニアとデビッド・ロックフェラー

証拠：Covidプランデミックは少なくとも9.11と同じ時期に計画されていた　Ethan Huff

注目に値するA・ファウチ博士　F. William Engdahl　（ゲイツ財団陰謀団の嘘つき博士）

Covidのバイオテロの痕跡は、CCPの協力者であるアントニー・ファウチとピーター・ダスザックにさかのぼる　Lance D Johnson

COVID-19コロナウイルス：2003年にCDCによって台本書きされたか？ デッドゾーン　ペスト　By Bill Sardi

映画『感染（コンテイジョン）』はコロナウイルス発生への青写真をどのように用意したか　Vigilant Citizen

COVID-19 封鎖：グローバルな人間実験　By　Vigilant Citizen　＋　Sylvia Brownie 『End of days』　(2008)

ロックフェラー財団は2010年に現在の「パンデミック」を脚本化していた　2020-10-24 17:27:00

「猫インフルエンザ」に関するシンプソンズのクリップは途方もなく予言的だった　By Vigilant Citizen 　（シークレット・メディアの陰謀団＆ワクチン）

いつまで踊ってるの？：2012年ロンドンオリンピック開会式で予告されたコロナウイルス

今、2012年のロンドンオリンピックの開会式を振り返るのは理にかなっている　newensign

グローバル・ロックダウンを想定した2013年のロックフェラー論文　John B

コロナウイルス・ワクチンにおけるパターン識別：DNA-オリガミの自己組織化効果　Mik Andersen　１、２、３

ファイザー、DNAナノロボットでイド・バチェレと提携　OUTRAGED HUMAN　１、２

ファイザーは、mRNA注射薬にDNAを永久に改変する「ナノボット」が含まれていることを認めている　Baxter Dmitry

グラフェン酸化物が秘伝のソースに？　パート２　Maryam Henein

グローバリストのクラウス・シュワブは、2016年に「グローバル・ヘルス・パス」と呼ばれるマイクロチップの埋め込みを呼びかけていた　Ethan Huff

カンシノ、ファイザー、シノファーム、アストラゼネカ、スプートニクのワクチンバイアルに酸化グラフェンとマイクロテクノロジーを確認　Orwell City

「SPARSパンデミック2025-2028」シミュレーションは、COVID-19に続く新たなコロナウイルスプランデミックの詳細を明らかにしている　HAF　（2017）

2017年の報告書では、Covidワクチンは有毒であるとされている　by Derrick Broze

2017年、ソロスは「2020年までに」愛国者を黙らせる計画を起草　 by Brabantian

「ポピー」－ パフォーマンス・アーティストがCovid 心理作戦を予言していた　CR

2018年、SARS2はUNCの冷凍庫にあった　Jim Haslam

パンデミックが目的を持って計画されたことの証明：数百万個のCOVID-19テストキットが 　2017年と2018年に販売された

パンデミックは計画されていたのか？　概要編　＋　世界保健機関はテロリストが運営している　ほか

COVID-19の起源を解明する：DEFUSE提案に迫る　Medriva Correspondents　＋　炎上するバイオ医薬品複合体　John leake

グローバル生物戦争：米国が運営するバイオラボは、ウクライナだけではない：アフリカやアジア太平洋地域にも配備されている　Ethan Huff

2019年にイタリアで記録されたCovidのアウトブレイクは、米国のバイオ研究所が引き起こしたのか？　Dr. Peter F. Mayer

病原体ゲーム絵巻　超速フラッシュバック　＋　数ヶ月を2週間に！迅速・簡便な新型コロナウイルス人工合成技術を開発　松浦善治教授

それは、ワクチンではありません。それは、あなたを病気にするように作られているのです。　Dr. David Martin

ファイザーの研究責任者：Covidワクチンは女性の不妊化である　Health & Money News
元ファイザーの科学者が武漢コロナウイルスに関する政府と大企業の欺瞞を警告　Ramon Tomey
実験的なcovidワクチンは、重要な臓器や血流に炎症性のスパイクタンパク質を溢れさせる生物兵器のデリバリーシステムである　Lance D Johnson
転移可能要素、胎盤の発達、卵子の活性化。細胞ストレスとAMPKがつなぐジャンプ遺伝子が人間の生命を生み出す　Jahahreeh Finley
シンシチン-１
爆弾：致命的な血栓の原因はcovidスパイクタンパク質であり、（意図的に）すべてのcovidワクチンに含まれていることを、ソーク研究所の科学論文が明らかにした　Mike Adams
Covidワクチンのスパイクタンパクは男性の生殖能力も攻撃する　Ethan Huff
人口削減警報: 衝撃的な新しい研究では、covidワクチンが「自然流産」によって5つの妊娠のうち4つを終了させることが明らかになった　Mike Adams

ファイザーのCOVID-19ワクチン1回分には2000億個以上のDNA断片が含まれており、この断片がヒトのDNAに取り込まれてがんを引き起こす可能性がある　Lance D Johnson

英国政府報告書によると、2029年までに英国のすべての空港が閉鎖され、気候詐欺の目標を達成するために牛肉と羊肉の食用が禁止される　The Exposé

ワクチンパスポートはパンデミックが始まる前から計画されていた　GreatGameIndia

シリーズ『ユートピア』がいかに2020年を不気味に予測したか　By Vigilant Citizen

2020年4月のロックフェラー財団の論文が米国の人口全体の検査と追跡を促している　By Makia Freeman

SARS-CoV-2/Wuhan-1/2020ウイルスは、米国疾病予防管理センター（CDC）からAndrew Pekosz博士に提供された

COVID発生前、ゲイツは製薬会社、CDC、メディア、中国、CIAとともにワクチン安全擁護者のソーシャルメディア検閲を計画していた　Robert F. Kennedy, Jr.

CDCは、covid-19スキャンダルの当初から中国共産党と連携していた　Lance D Johnson

WHOの真のアジェンダ：中国をモデルにした新世界秩序　By　Vigilant Citizen
コロナウイルスCOVID-19パンデミック：本当の危険は「アジェンダID2020」 By Peter Koenig
マイクロソフト、ビッグテック連合がロックフェラー出資のCOVIDパスポートを開発している　Steve Watson
ビル・ゲイツは、COVID-19ワクチンを受けた人間を特定するための「デジタル証明書」を要求　By Vigilant Citizen

そう、ビル・ゲイツが言っていた。これがその証拠だ　Robert F. Kennedy, Jr.

禁止されたドキュメンタリー – ビル・ゲイツがマイクロソフトからワクチンに切り替えた理由

ビル・ゲイツと他の大量殺戮サイコパス　helpfreetheearth ＋　エプスタインの友達 ダーショウィッツ、強制ワクチンへの支持を表明　＋　ロシア公共放送が驚愕の報道！！

マスク、社会的距離、仮想学習は、現実に、アメリカでの共産主義のインストールが目的である　S.D. Wells

プランデミックはグローバリストの策略－「最悪の事態はまだこれから来る」　by Steven Guinness

オーストラリア、親の同意なしに24,000人の子供に注射を行うための、スタジアム規模のcovid死の注射処理センターを立ち上げる　Ethan Huff

中国の反体制自由活動家、陳光誠が西側諸国に対して「我々の戸口にある」社会信用システムに警告を発した Claire Chretien

パンデミック・スリラー映画『ソングバード』は純粋な予測プログラミングになるだろう　By Vigilant Citizen　＋

クラウス・シュワブの「15分都市」構想が世界各地で進む　Redacted

非電離放射線を長時間浴びると、さまざまな健康被害が引き起こされる　Orwell City

ノルウェー人男性、陰謀に関する真実をフェイスブックに投稿し精神科に拘留される　Rhoda Wilson

オバマ夫妻製作の不穏な映画『世界を置き去りにする』に隠された象徴性　Vigilant Citizen　１、　２

NASAのブルービーム計画 － セルジュ・モナストが語る　Patricia Harrity　１

世界保健機関（WHO）が再び違法行為に踏み切ろうとしている　Senator Malcom Roberts

WHO保健政策の核心にある腐敗と欺瞞　Judy Wilyman PhD

COVID-19は、遺伝子兵器と生物学的実験を何波にもわたって住民に導入するための試験運用だった　Lance D Johnson

マコウ：すべてが台本通り　１

4年後、Fox NewsはCOVID起源の陰謀と隠蔽工作をすべて認めた　Lance D Johnson

日本から世界へのメッセージ－井上正康教授　Patricia Harrity

https://tyuuta1.com/wadai430/

「神の棒」によって破壊される34のサタニック遺跡のリストと写真

http://blog.livedoor.jp/sagittariun-shinjituwomiru/archives/40529069.html

KINGDOM

https://youtu.be/MA3iscoypcY?si=ntFHr599JdV3m0KV

ブログ
https://blg.hmasunaga.com/2016/10/24/post-179/

意見広告pdf(日刊ゲンダイ20161021)
https://blg.hmasunaga.com/hmadmeqdd/wp-content/uploads/2016/10/5e9cd6d8713b0a1ac6c650d2177c94a4.pdf

https://t.me/thefinalwakeupcallchannel/14767

完全な開示
ピーター・B・マイヤー著 – 4月20日。 2024年

目に見えない世界との関係は、通常の人間にとって善と悪の概念の下にあるアルコンと呼ばれる非人間的実体または精神寄生虫のせいで非常に複雑です。

重要なのは、イルミナティが私たちに信じ込ませているような、アヌンナキは私たちの創造者ではないということです。 彼らは私たちを奴隷として利用できるように私たちを操作しただけです。

ゼカリア・シッチン氏によると、アヌンナキは私たちの霊的側面の源では決してなく、純粋な愛のエネルギーから神によって創造されました。

目に見えないマスターは、不死の存在である知覚できない異次元の存在に属しており、秘密結社で慎重に選ばれた弟子に対する難解な教えの中でのみ宣言されています。

大衆文化とは対照的に、本当の隠れマスターはダークサイドのエイリアンではなく、慈悲深いエイリアンです。 慈悲深い存在たちは私たちの生活を支配したりコントロールしたりする必要はありません。 これは普遍的なオカルト法に違反します。

しかし、闇のエリートたちはこれらの法則を超えて立ち上がろうとしており、物質世界の守護者として行動しています。言い換えれば、彼らはアルコンであり、ほとんどのイスラム教徒と同様、オカルトエリートやオカルトエリートに雇われている、最も危険な精神内寄生虫です。 私たち国民を欺き、操作する諜報機関。

12 本の DNA 鎖のうち 10 本が切断されたことで、私たちの可能性は限られてしまいました。 一部のエイリアンは人類の遺伝子操作を助けましたが、アヌンナキはその後、12本のDNA鎖のうち10本を切断することで人類の遺伝学を破壊し、人類をエリートのために奴隷化しました。
https://cinemaphile.com/watch?v=qpcfZzx8xY0

これらの切断された鎖は、科学者によってジャンク DNA と呼ばれています。 実際、私たちは能力のほとんど、あるいはほとんどすべてを失い、独立して生き残ることができるより多くの奴隷を複製するためだけに、残った2本のDNA鎖に調整されています。 12 本の DNA 鎖がすべて復元されると、私たちは驚くべき能力を持つようになります。

これにより、大多数の人間は現在脳の 12 パーセントしか使用していないのに対し、私たちは再び脳を 100 パーセント使用できるようになります。

宇宙人は、私たちの創造的能力と多才な特質を備えた私たちの DNA 兵器を欲しがるでしょう。 彼らは私たちの創造性を羨望しており、それが私たちを不滅にします。 聖書にあるように、私たちは創造主に似せて造られています。 イエスが奇跡を行ったとき、こう言いました。

「これらのこともできます。」

アヌンナキが DNA の 12 鎖のうち 10 本を切断して私たちを奴隷にした時代以前、人類はこのようにして機能することができたのです。

カバールが作り出したあらゆるものは今、段階的に解体されつつあります。 最も重要なことは、彼らの世界的な不換紙幣経済は、ディープステートにその世界的支配を放棄させるために収縮しつつあるということです。

法定金融システムは、現地通貨、つまり、無価値になったり偽造されたりすることのない量子金融システムと統合された、金または銀を裏付けとしたソブリン通貨システムに置き換えられます。 これがGESARA後の世界の基礎です。
https://t.me/thefinalwakeupcallchannel

https://t.me/thefinalwakeupcallchannel/14781

創造的破壊
Peter B. Meyer 著 – 2024 年 4 月 21 日

事実;

• 「世界的な法定通貨の50年にわたる実験の結果として生じている混乱は、実質価値のある通貨への回帰を要求している。産油国が石油の代わりに金やそれに相当するものを要求する日が近いことを私たちは知るだろう。 (ペトロ)ドルかユーロは早ければ早いほど良いです。

• リチャード・デイは 1969 年の会合で、経済危機、大量失業、大量移民によって、古くから確立されたコミュニティが破壊されるだろうと語った。

ダムが決壊し始める
大衆の覚醒は世界が待ち望んでいたものです。 新型コロナウイルスのパンデミックが、ワクチン中毒によって自発的に国民を殺すためにでっち上げられたことに大衆が気づいたとき、水門が開きます。 人々は激怒し、あらゆる権威に対して復讐を求めます。 これは世界が待ち望んでいた瞬間です。

人々は欲しいものや市場から期待しているものを手に入れていません。 彼らは当然のことを手に入れています。 しかし、半世紀にもわたる失敗、失敗した投資、失敗した企業、デフォルトした個人の失敗がありました。 非常に多くの間違いを正さなければならない場合、それは不況と呼ばれ、現在起こっているように経済全体が悪化する場合、それは恐慌と呼ばれます。

市場が何らかの修正を加えようとするたびに、中央銀行家はより多くの紙幣を印刷し、より容易な信用をもたらしました。 何年も前に倒産するはずだった企業が、負債をさらに深め続けた。 住宅所有者も借金を負い続けた。

・「矯正の力は、それに先立つ欺瞞と同等であり、反対である。」

資本主義は、経済学者のヨーゼフ・シュンペーターが呼んだプロセスを通じて機能します。

• “創造的破壊”。

間違いを打ち破り、新しいイノベーションや新しいビジネスに道を譲ります。 いわゆる「創造的破壊」。

残念ながら、これは政府や多くの人々が望んでいることと矛盾しています。 人は間違いを犯すと、自分には責任がないと主張します。 「この危機を誰が予想できたでしょうか？」 彼らが聞く。 そして、「損失は他の誰かが支払ってください」と言います。

現在、中央銀行は「バブル時代に規制上の責任を誤って管理し、資金管理を誤った貸し手を保護するために、管理を誤った企業を救済した」。

全世界が知っているように、資本主義システムは今日米国にとっても世界にとっても機能しておらず、危機から危機へと、そのたびに前回よりもさらに深刻化しています。

中央銀行が「創造的破壊」のプロセスを遅らせ、注意をそらそうとすればするほど、回復に時間がかかり、最終的なコストは増大する。

・「うつ病の重症度は、それを阻止しようとする政府の取り組みと逆相関している。」

お金を印刷することは、既存の通貨、つまり人々が稼いで貯めたお金の価値を盗むこと、言い換えれば、古いお金の価値を盗むことです。

苦労して稼いだお金を貯めた人々は、購買力の一部を失っています。 彼らは確かに、お金を打ち切られることに決して同意しませんでした。 さらに悪いことに、彼らは自分たちのお金に何が起こっているのかまったく知りませんでした。 それで、誰が彼らに返済するのでしょうか？ 誰でもない。
https://t.me/thefinalwakeupcallchannel

https://t.me/rtnews/61195

チャド、ニジェールに続き米軍撤退要求

チャドがアジ・コッセイ空軍基地に駐留する米軍の撤退を要求したのは最近になって以来、アフリカはもはや米軍の駐留を容認していないようだ。

ニジェールは以前、米軍に国外退去を要請した。

https://youtu.be/H69YmuM-_KI?si=uN45qS6AzKKo8pSL

ニコニコ動画

https://www.nicovideo.jp/watch/sm41321420

https://x.com/N4er5BANKPkQFQe/status/1781563691730870536

Twitter(X)
接種が免除されて滑りました
https://x.com/k3bixG6s6gzLaYM/status/1780788952838127681

健発１２０９第２号
令和２年 12 月９日

（宛先）
都 道 府 県
各 保 健 所 設 置 市 衛生主管部（局）長 殿
特 別 区

(差出人)
厚 生 労 働 省 健 康 局 長
（ 公 印 省 略 ）

予防接種法及び検疫法の一部を改正する法律等の施行について
https://www.yoboseshu-rc.com/files/libs/994/202111241134302752.pdf

：
：
（４）一の（１）の予防接種を行う場合において、第８条又は第９条の規定は、新型
コロナウイルス感染症のまん延の状況並びに予防接種の有効性及び安全性に関
する情報その他の情報を踏まえ、政令で、当該規定ごとに対象者を指定して適用
しないこととすることができるものとすること。（附則第７条第４項関係）
：
：

おまけ、とても紛らわしい!

医政発１２０９第22号
産情発１２０９第２号
健 発１２０９第２号
生食発１２０９第７号
保 発１２０９第３号

令 和 ４ 年 12 月 ９ 日

（宛先）
都 道 府 県 知 事
各　保健所設置市長 殿
特 別 区 長

（差出人）
厚 生 労 働 省 医 政 局 長
厚生労働省大臣官房医薬産業振興・医療情報審議官
厚 生 労 働 省 健 康 局 長
厚生労働省大臣官房生活衛生・食品安全審議 官
厚 生 労 働 省 保 険 局 長
（ 公 印 省 略 ）

「感染症の予防及び感染症の患者に対する医療に関する法律等の一部を改正する法律」の
公布及び一部施行について（通知）
https://www.mhlw.go.jp/content/001022538.pdf

https://www.youtube.com/live/fsuORk9Z00E?si=mqqV-9E5CxDBAs7u

ニコニコ動画

https://www.nicovideo.jp/watch/so43657573?ref=search_key_video&playlist=eyJ0eXBlIjoic2VhcmNoIiwiY29udGV4dCI6eyJrZXl3b3JkIjoiXHUzMGQxXHUzMGYzXHUzMGM3XHUzMGRmXHUzMGMzXHUzMGFmXHU2NzYxXHU3ZDA0Iiwic29ydEtleSI6ImhvdCIsInNvcnRPcmRlciI6Im5vbmUiLCJwYWdlIjoxLCJwYWdlU2l6ZSI6MzJ9fQ&ss_pos=1&ss_id=37aa503c-153d-4590-8da7-fea82329320b

拡散希望動画ちゃん寝る さん
ニコニコ動画

https://www.nicovideo.jp/watch/sm43662111?ref=search_key_video&playlist=eyJ0eXBlIjoic2VhcmNoIiwiY29udGV4dCI6eyJrZXl3b3JkIjoiXHUzMGQxXHUzMGYzXHUzMGM3XHUzMGRmXHUzMGMzXHUzMGFmXHU2NzYxXHU3ZDA0Iiwic29ydEtleSI6ImhvdCIsInNvcnRPcmRlciI6Im5vbmUiLCJwYWdlIjoxLCJwYWdlU2l6ZSI6MzJ9fQ&ss_pos=11&ss_id=37aa503c-153d-4590-8da7-fea82329320b

パンデミック条約反対 池袋デモ行進 1/3
https://www.nicovideo.jp/watch/sm43662453

パンデミック条約反対 池袋デモ行進 2/3
https://www.nicovideo.jp/watch/sm43662495

パンデミック条約反対 池袋デモ行進 3/3
https://www.nicovideo.jp/watch/sm43662533

Telegram (https://t.me/neohistory1/870812)
sir Cheeze in TARTARIA JAPAN chat

https://t.me/neohistory1/870850

https://x.com/masami777777/status/1779087345784140096

https://www.epochtimes.jp/2024/04/217796.html

大紀元
【報道】パンデミック条約に反対するデモ、池袋に1万人超が集結
https://x.com/epochtimes_jp/status/1779178548521296379

https://newssharing.net/rfkjr-who

我那覇真子 Masako GanahaさんのX投稿動画
【生配信】パンデミック条約 国際保健規則改定反対デモ行進の様子
https://x.com/ganaha_masako/status/1779010769314824354

一旦途切れたのでこちらで再開してます。
https://x.com/MGOML_X2OA/status/1779052016448524683

https://youtu.be/7i0By6o7d1o?si=pEmeM1t8yjID6eCl

HOME
https://themillenniumreport.com/

TODAY’s POSTS
https://themillenniumreport.com/author/themillenniumreport/

G翻訳
HOME
https://themillenniumreport-com.translate.goog/?_x_tr_sl=auto&_x_tr_tl=ja&_x_tr_hl=ja&_x_tr_pto=wapp

TODAY’s POSTS（今日の投稿）
https://themillenniumreport-com.translate.goog/author/themillenniumreport/?_x_tr_sl=auto&_x_tr_tl=ja&_x_tr_hl=ja&_x_tr_pto=wapp

https://hotnews8.net/

マスコミが報じないニュース ＆ 気になる情報メモ
https://hotnews8.net/DSsokuho/

https://hotnews8.net/society/communism/deep-state-cultural-marxism

https://hotnews8.net/society/deep-state/color-revolution

https://x.com/kharaguchi/status/1775976241394544931

https://x.com/kharaguchi/status/1776326003142672864

米国が戦争にわざわざ介入しないことを明らかにすることは、イランがイスラエルに報復攻撃を行うことに関するハアードルを下げる。
ＤＳが戦争状態を作り出す常套手段にみえる。

https://x.com/kinoshitayakuhi/status/1766351236151046525

皆さんには納税を拒否する義務があります。

ニュルンベルク戦争犯罪法廷より
（日本語自動機械翻訳）
https://worldbeyondwar-org.translate.goog/crime-pay-tax/

衆議院インターネット審議中継

https://www.shugiintv.go.jp/jp/index.php?ex=VL&deli_id=55102&media_type=

https://m.youtube.com/watch?v=OA_9YCghM2U&noapp=1

https://jsn.or.jp/journal/document/56_8/1218-1224.pdf

https://aburano-hanashi.kuni-naka.com/4527

https://jglobal.jst.go.jp/detail?JGLOBAL_ID=202202214545047878

リチャードコシミズ氏、紅麹サプリに含まれるスタチンとワクチンの相互作用について言及

https://x.com/ric_koshimizu/status/1774250402265039251?s=20

https://www.healthy-pass.co.jp/blog/20210113-2/

食事由来のビタミンDや、皮膚において紫外線によって生成したビタミンDは、肝臓で25ヒドロキシビタミンD (25-OH-D3) になります。

続いて腎臓で活性型の1α-25ジヒドロキシビタミンD (1,25 (OH) 2D3) に代謝され、体内で利用されます。

ビタミンDの活性化にはマグネシウムが関わっており、マグネシウムが不足しているとビタミンDの活性化に影響が表れる可能性があります😣

https://muramo10.hatenablog.com/entry/2021/12/13/081945

7-デヒドロコレステロールは紫外線により皮膚でビタミンD3（コレカルシフェロール）となる。ビタミンＤ3は2つのヒドロキシル化（水酸基 －OH の導入）を経て活性化される。まず、ビタミンD3は肝臓で、25-ヒドロキシラーゼにより25(OH)D3（カルシジオール）となり、脂肪組織に貯蔵される。次に、腎臓、免疫細胞、肺上皮細胞や他の器官で1αヒドロキシラーゼにより活性型ステロイドホルモンである1,25(OH)2D3（カルシトリオール）となり、カルシウム代謝を調節するとともに自然免疫系と獲得免疫系を調節する。

ちなみに、ビタミンD3サプリはコレカルシフェロールであり、骨粗鬆症で整形外科医が処方するエディロールやアルファロールなどはカルシトリオールである。

https://muramo10.hatenablog.com/entry/2021/07/29/093106

https://alzhacker.com/role-of-magnesium-in-vitamin-d-activation-and-function/

ビタミンD3（コレカルシフェロール）は、太陽光を浴びると皮膚で生成される。したがって、ビタミンDは本物のビタミンではない。日光を十分に浴びている人は、サプリメントを摂取する必要はない。30,32,59,60 ビタミンDは、D3（動物由来）またはD2（非動物由来）のいずれも、重要な生物学的活性を持っていない。ビタミンDは、動物由来のD3でも、非動物由来のD2でも、生物学的活性を持たず、肝臓や腎臓で処理されて、生物学的活性を持つ1,25-ジヒドロキシビタミンD（1,25[OH]2D）になる必要があるとされている。この活性化プロセスは2つのステップで行われる。(1）肝臓でコレカルシフェロールが25-水酸化酵素によって25-ヒドロキシコレカルシフェロール（25[OH]2D）に水酸化され、（2）腎臓で25-ヒドロキシコレカルシフェロールが1α水酸化酵素によって1,25(OH)2Dに変換される1,2,32,38,61。肝の25-水酸化酵素と腎の1α-水酸化酵素の両方の酵素活性は、マグネシウム依存性のプロセスである。ビタミンDは、キャリアータンパク質に結合して血液中を輸送されるが、その主要なキャリアーはビタミンD結合タンパク質である。重要なことは、ビタミンD結合タンパク質の活性もまた、マグネシウム依存性のプロセスであるということである（図2）62,63。

図2　ビタミンDの合成におけるマグネシウムの役割

マグネシウムは、ビタミンDの合成と活性化に不可欠な補酵素

柏病院　　ビタミンDの基礎知識（がんとの関連）第2版

https://www.jikei.ac.jp/hospital/kashiwa/sinryo/40_02w7.html

25（OH）D（ビタミンD）

ビタミンD3の体内代謝
1.　ビタミンＤ3は人の皮膚で作られ、体中を循環する。
2.　7-デヒドロコレステロール（7-dehydrocholesterol）はビタミンD3の前駆体（プロビタミンD3）である。
3.　アセチル CoA（アセチルコエンザイムＡ：アセチル補酵素A）から7-デヒドロコレステロールができる。7-デヒドロコレステロールは還元されるとコレステロールになり、ステロイドホルモンになる。
4.
5.

動物
7-デヒドロコレステロール　⇒　紫外線と体温　⇒　ビタミンD3
（ビタミンD3の前駆体）　　　　　　　　　　　　　(コレカルシフェロール)
（プロビタミンD3）

新型コロナワクチンの接種状況を可視化する目的で、ダッシュボードを提供しています。

イベルメクチンの飲み方

https://www.nicovideo.jp/watch/sm40895382

コロナ臨床患者：　保険が効く（医療機関が国費請求ができる）
コロナ後遺症患者：　保険が効かない（薬事法に引っかかる＝国が認めていない）、自己責任で服用する必要あり
コロナワクチン後遺症患者：　保険が効かない（薬事法に引っかかる＝国が認めていない）、自己責任で服用する必要あり

#193_ワクチン後遺症の現実④～なぜ効くのか？ どう効くのか？ イベルメクチン服用者の証言　長尾チャンネル
https://www.nicovideo.jp/watch/sm41576777

https://youtu.be/uNo72B2Cdpg?si=9rlrg7VctHBMA_Fm

【本日の記者会見】キーワードは「ビタミンD」【河北新報 武田記者 とりあえずお疲れ様でした。】

https://youtu.be/Si7zZ4cPcUk?si=GqmjCvBJUUFTN-6v